Overdiagnosis and overtreatment of breast cancer: Estimates of overdiagnosis from two trials of mammographic screening for breast cancer (original) (raw)

Abstract

Randomised controlled trials have shown that the policy of mammographic screening confers a substantial and significant reduction in breast cancer mortality. This has often been accompanied, however, by an increase in breast cancer incidence, particularly during the early years of a screening programme, which has led to concerns about overdiagnosis, that is to say, the diagnosis of disease that, if left undetected and therefore untreated, would not become symptomatic. We used incidence data from two randomised controlled trials of mammographic screening, the Swedish Two-county Trial and the Gothenburg Trial, to establish the timing and magnitude of any excess incidence of invasive disease and ductal carcinoma in situ (DCIS) in the study groups, to ascertain whether the excess incidence of DCIS reported early in a screening trial is balanced by a later deficit in invasive disease and provide explicit estimates of the rate of 'real' and non-progressive 'overdiagnosed' tumours from the study groups of the trials. We used a multistate model for overdiagnosis and used Markov Chain Monte Carlo methods to estimate the parameters. After taking into account the effect of lead time, we estimated that less than 5% of cases diagnosed at prevalence screen and less than 1% of cases diagnosed at incidence screens are being overdiagnosed. Overall, we estimate overdiagnosis to be around 1% of all cases diagnosed in screened populations. These estimates are, however, subject to considerable uncertainty. Our results suggest that overdiagnosis in mammography screening is a minor phenomenon, but further studies with very large numbers are required for more precise estimation.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (16)

  1. Tabar L, Vitak B, Chen HH, Duffy SW, Smith RA: The Swedish Two-County Trial twenty years later: updated mortality results and new insights from long term follow-up. Radiol Clin Nth Am 2000, 38:625-651.
  2. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AMF, Chen HHT: The randomized trials of breast cancer screening: what have we learned? Radiol Clin Nth Am 2004, 42:793-806.
  3. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 360:724.
  4. Paci E, Warwick J, Falini P, Duffy SW: Overdiagnosis in service screening: should the increase in breast cancer incidence rates necessarily be a cause for concern? J Med Screen 2004, 11:23-27.
  5. Anttila A, Koskela J, Hakama M: Programme sensitivity and effectiveness of mammography service screening in Helsinki, Finland. J Med Screen 2002, 9:153-158.
  6. McCann J, Treasure P, Duffy SW: Modelling the impact of detecting and treating carcinoma in situ in a breast screening programme. J Med Screen 2004, 11:117-125.
  7. Evans AJ, Pinder SE, Ellis IO, Wilson AR: Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 2001, 8:149- 151.
  8. Bjurstam N, Björneld L, Warwick J: The Gothenburg Breast Screening Trial. Cancer 2003, 97:2387-2396.
  9. Breast Cancer Research December 2005 Vol 7 No 6 Duffy et al.
  10. Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, Ljungquist U, Lundstrom B, Manson JC, Eklund G, et al.: Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985, 1:829- 832.
  11. CODA: Convergence Diagnostics and Output Analysis Soft- ware 0.4 [http://www.mrc-bsu.cam.ac.uk/bugs/classic/coda04/ readme.shtml]
  12. Ernster VL, Barclay J: Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 1997, 22:151-156.
  13. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, et al.: Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002, 94:1546-1554.
  14. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW: Quan- tifying the potential problem of overdiagnosis of ductal carci- noma in situ in breast cancer screening. Eur J Cancer 2003, 39:1746-1754.
  15. Zahl PH, Strand BH, Maehlen J: Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. Br Med J 2004, 328:921- 924.
  16. Vainio H, Bianchim F: Breast Cancer Screening. Lyon: IARC Press; 2002.